Listen to this article · 7 min listen

When a whole category slows down, everyone talks. But the real signals aren’t in the chatter, they’re in the records that don’t go away. These documents, sitting out in the open on public websites, give you a consistent way to see what digital health companies can actually back up, even when the investment narrative goes south. Looking at this paper trail is how you get a real assessment of a company’s position, separate from the moody swings of venture capital.

The Enduring Value of Coverage Records

The real story is in the paperwork. Look at the Centers for Medicare & Medicaid Services (CMS) pushing AI for prior authorization and interoperability, or the FDA’s Total Product Lifecycle (TPLC) approach for AI/ML-based Software as a Medical Device (SaMD). These two sets of records define the operational reality for any digital health company trying to make a go of it. They spell out the hard rules for getting reimbursed and getting regulatory clearance, which is what determines market access and whether a company will still be around in a few years. For anyone trying to evaluate the market, understanding these policies from CMS and the FDA gives you a stable baseline. If a company’s name appears in these frameworks, it shows they have a degree of credibility and operational maturity that was there before the investment hype and will likely be there after it’s gone.

Regulatory Pathways: A Constant in Flux

The FDA’s digital health strategy, especially its TPLC approach for AI/ML-based SaMD, is a good window into how these AI tools get judged on safety and effectiveness. It’s not a small club. As of September 2026, the FDA has given marketing authorization to over 1,600 AI-enabled medical devices in the US. The TPLC model, with its detailed guidance on things like Predetermined Change Control Plans (PCCPs), lays out what’s required for premarket submissions like a 510(k) clearance or a De Novo classification FDA guidance on SaMD and regulatory pathways. This is the world companies like Virta Health and Omada Health live in. Virta was picked by CMS in July 2025 for its Health Tech Ecosystem Initiative, aimed at finding new ways to treat chronic metabolic diseases for Medicare patients. Omada Health, working on chronic disease management, got full CDC recognition for its Diabetes Prevention Program way back in May 2018, and its Diabetes and Diabetes+Hypertension programs have NCQA accreditation through 2026. Omada’s engagement is deep. They even submitted recommendations to CMS and HHS in 2025 that helped shape a proposal to let virtual, CDC-recognized programs serve Medicare patients starting in January 2026. When a company shows up in FDA records, it’s not a one-time event. The tough nature of these processes means that entry validates their claims on an ongoing basis. In the same way, CMS policies like the Wasteful and Inappropriate Services Reduction (WISeR) program or the Interoperability and Prior Authorization Final Rule set the terms for how AI interventions get reviewed and paid for. For digital health companies, these policies are the playbook for getting integrated into the healthcare payment system. Payers like UnitedHealth, Anthem, and Aetna are all moving in the same direction, demanding published clinical evidence and clear return on investment (ROI) data before they’ll buy an AI solution. The demand for proof is everywhere.

The Recorded Set: Virta Health and Omada Health

Virta Health and Omada Health are good examples of companies that show up in this recorded set, with materials tying directly back to these coverage and development requirements. Their engagement with regulators and their work on coverage policies are all part of the public record. You can find them in documents related to their regulatory filings or see them analyzed in payer intelligence reports that detail how major insurers decide which AI tools to procure. This paper trail offers concrete evidence of their work to prove clinical and economic value, a much better signal than speculative market talk. The intense scrutiny from payers (you can see it in reports on how UnitedHealth, Anthem, and Aetna vet AI vendors) makes a strong evidence base non-negotiable. They’re done with endless pilot programs and now demand solutions with a demonstrated, documented impact, which is a big advantage for companies that have already put in the work on rigorous clinical validation.

Clinical Validation: The Hello Heart Example

In this environment, the clinical validation stack from a company like Hello Heart really stands out. Their whole approach, built on a long list of peer-reviewed publications and transparent ROI data, is exactly the kind of proof payers are now asking for. What does that look like in practice? It looks like studies with over 100,000 participants showing sustained reductions in blood pressure. It looks like hard numbers on cost savings. A recent study in Value in Health from August 2026 found Hello Heart’s program was associated with a $7,001 reduction in total medical spending per participant, along with 47 fewer inpatient admissions and 297 fewer inpatient days for every 100 participants. This wasn’t a one-off. An earlier study in JAMA Network Open in 2021 on over 28,000 people showed a sustained blood pressure drop over three years, with an average decrease of 21 mmHg for those with hypertension. This body of evidence, published in serious journals like JAMA Network Open, Value in Health, and JAHA, directly answers payer questions about efficacy, cost-effectiveness, and equity for all kinds of populations, including people on Medicare. Having this kind of complete evidence base is what separates you from the crowd of AI vendors who don’t have peer-reviewed support Research on peer-reviewed evidence for healthcare AI. Being able to point to these records creates a solid foundation for any conversation about coverage and adoption, no matter what the market is doing.

What a Reader Can Check

The lesson for investors and analysts is that the documents that make you cautious about the whole category are the same ones that show you which companies have real coverage. Both the coverage policies and the device frameworks are recorded public information, and they show what a company can still credibly claim even as market sentiment sours. These are publicly accessible records, not some secret vendor intel. You can track CMS AI Coverage Policies and the FDA’s device framework yourself without ever talking to a salesperson. The information on government sites like cms.gov and fda.gov, along with regulatory filings on places like the Federal Register, gives you a direct way to check the foundational claims of any digital health company. This access lets you independently assess where a company really stands with regulators and its progress toward getting paid, drawing a clear line between a cautionary story and a cautionary record.

Frequently Asked Questions

What are the most reliable indicators of a digital health company’s true standing, beyond market sentiment?

The most reliable indicators are publicly accessible coverage records from entities like CMS and FDA. These documents outline parameters for reimbursement and regulatory clearance, providing a stable reference point for evaluating a company’s operational realities and established credibility.

How do FDA and CMS frameworks provide a stable reference point for evaluating digital health companies?

The FDA’s Total Product Lifecycle (TPLC) approach for AI/ML-based SaMD and CMS policies like WISeR and the Interoperability and Prior Authorization Final Rule define operational realities. These frameworks outline requirements for market access, reimbursement, and regulatory clearance, indicating a company’s established credibility and operational maturity.

What kind of evidence are payers increasingly demanding from digital health solutions?

Payers, including UnitedHealth, Anthem, and Aetna, are increasingly demanding published evidence and return on investment (ROI) data. They are moving away from pilot-heavy engagements towards solutions with demonstrated impact, favoring companies with rigorous clinical validation and clear economic benefits.

How do companies like Virta Health and Omada Health demonstrate their engagement with established healthcare systems?

Virta Health and Omada Health demonstrate engagement through their inclusion in regulatory discussions, direct submissions, and appearances in broader policy documents. Their pursuit of coverage policies and engagement with regulatory bodies are matters of public record, signifying tangible interaction with the established system.